Empiric therapy for febrile neutropenia: what are the choices?

References

• Schimpff SC. Empiric antibiotic therapy for granulocytopenic cancer patients. Am. J. Med.80, 13–20 (1986).
   PubMed Web of Science ®Google Scholar
• Klastersky J, Vamecq G, Cappel R, Swings G, Vandenborre L. Effects of the combination of gentamycin and carbenicillin on the bactericidal activity of serum. J. Infect. Dis.125, 183–186 (1972).
   PubMed Web of Science ®Google Scholar
• Rolston KW, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch. Intern. Med.152, 283–291 (1992).
   PubMed Web of Science ®Google Scholar
• Talcott JA, Siegel RD, Finberg R et al. Risk assessment in cancer patients with fever and neutropenia: a prospective, two center validation of a predictive rule. J. Clin. Oncol.10, 316–322 (1992).
   PubMed Web of Science ®Google Scholar
• Rolston KW. New trends in patient management: risk-based therapy for febrile patients with neutropenia. Clin. Infect. Dis.29, 515–521 (1999).
   PubMed Web of Science ®Google Scholar
• Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia. Retrospective analysis of 410 episodes. Arch. Intern. Med.145, 1621–1629 (1985).
   PubMed Web of Science ®Google Scholar
• Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis.32(Suppl. 2), S146–S155 (2001).
   PubMed Web of Science ®Google Scholar
• Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J. Antimicrob. Chemother.55, 71–77 (2005). Erratum in: J. Antimicrob. Chemother.55, 990 (2005).
   PubMed Web of Science ®Google Scholar
• Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001–2002: the BSAC Bacteraemia Resistance Surveillance Programme. J. Antimicrob. Chemother.53, 1018–1032 (2004).
   PubMed Web of Science ®Google Scholar
• Akova M. Emerging problem pathogens: a review of resistance patterns over time. Int. J. Infect. Dis.10(Suppl. 2), S3–S8 (2006).
   Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price LS. Mechanisms of disease: the new β-lactamases. N. Engl. J. Med.352, 380–391 (2005).
   PubMed Web of Science ®Google Scholar
• Shitrit P, Gottesman BS, Katzir M et al. Active surveillance for methicillin-resistant Staphylococcus aureus (MRSA) decreases the incidence of MRSA bacteremia. Infect. Control. Hosp. Epidemiol.27, 1004–1008 (2006).
   Google Scholar
• Klastersky J, Paesmans M, Rubinstein ER et al. The Multinational Association for Supportive Care in Cancer Risk index: a multinational scoring system for identify low-risk febrile neutropenic cancer patients. J. Clin. Oncol.18, 3038–3051 (2000).
   Google Scholar
• Akova M, Paesmans M, Calandra T et al. A European Organization for Research and Treatment of Cancer-International Antimicrobial Therapy Group study of secondary infections in febrile, neutropenic patients with cancer. Clin. Infect. Dis.40, 239–245 (2005).
   PubMed Web of Science ®Google Scholar
• Somolinos N, Arranz R, Del Rey MC et al. Superinfection by Escherichia coli resistant to fluoroquinolones in immunocompromised patients. J. Antimicrob. Chemother.30, 730–731 (1992).
   PubMed Web of Science ®Google Scholar
• Kern WV, Andriof E, Oethinger M et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob. Agents Chemother.38, 681–687 (1994).
   PubMed Web of Science ®Google Scholar
• Cometta A, Calandra T, Bille J et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N. Engl. J. Med.330, 1240–1241 (1994).
   PubMed Web of Science ®Google Scholar
• Harvathova Z, Spanik S, Sufliarsky J et al. Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenia patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison of methicillin-sensitive bacteremia. J. Antimicrob. Agents10, 55–58 (1998).
   Web of Science ®Google Scholar
• Cordonnier C, Buzyn A, Leverger G et al. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin. Infect. Dis.36, 149–158 (2003).
   PubMed Web of Science ®Google Scholar
• Kern W, Kurrle E, Schmeiser T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy a review of 55 cases. Infection18, 138–145 (1990).
   PubMed Web of Science ®Google Scholar
• Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case–control study of predisposing factors. Clin. Infect. Dis.14, 1201–1207 (1992).
   PubMed Web of Science ®Google Scholar
• Klastersky J, Glauser MP, Schimpff SC. Prospective randomized comparison of three antibiotics regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob. Agents Chemother.29, 263–270 (1986).
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer with granulocytopenia. N. Eng. J. Med.317, 1692–1698 (1987).
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic patients. J. Infect. Dis.163, 951–958 (1991).
   PubMed Web of Science ®Google Scholar
• Meunier F, Zinner SH, Gaya H, Calandra T. Prospective randomised evolution of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors. Antimicrob. Agents Chemother.35, 873–878 (1991).
   PubMed Web of Science ®Google Scholar
• Zinner SH, Calandra T, Meunier F et al. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. JAMA272, 1183–1189 (1994).
   PubMed Web of Science ®Google Scholar
• Cometta A, Zinner SH, De Bock R et al. Piperacillin–tazobactam plus vancomycin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob. Agents Chemother.339, 445–452 (1995).
   Google Scholar
• Cometta A, Calandra T, Zinner SH et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob. Agents Chemother.43, 1108–1115 (1996).
   Google Scholar
• Kern WV, Cometta A, De Bock R, Langenaeken J. Oral intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N. Engl. J. Med.341, 312–318 (1999).
   Google Scholar
• Cometta A, Kern WV, De Bock R et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin–tazobactam monotherapy. Clin. Infect. Dis.37, 382–389 (2003).
   PubMed Web of Science ®Google Scholar
• Kaitsa I, Pappa V, Papageorgiou S et al. Bacteremic soft tissue infection due to panresistant Pseudomonas aeruginosa in a neutropenic BMT patient: an alarming case report. Presented at: 8th International Symposium on Febrile Neutropenia. Athens, Greece, January 2007.
   Google Scholar
• Guo Y. Urgency in treating febrile neutropenic patient harbouring multidurg resistant Pseudomonas: a case report. Presented at: 8th International Symposium on Febrile Neutropenia. Athens, Greece, January 2007.
   Google Scholar
• Deplano A, Denis O, Poirel L et al. Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa. J. Clin. Microbiol.43, 1198–1204 (2005).
   PubMed Web of Science ®Google Scholar
• Van Loon HJ, Vriens MR, Fluit AC et al. Antibiotic rotation and development of Gram-negative antibiotic resistance. Am. J. Respir. Crit. Care Med.171, 480–487 (2005).
   PubMed Web of Science ®Google Scholar
• Paterson DL, Ko WC, Von Gottberg A. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin. Infect. Dis.39, 31–37 (2004).
   PubMed Web of Science ®Google Scholar
• Owens RC, Owens CA, Holloway WJ. Reduction in vancomycin consumption in patients with fever and neutropenia. Clin. Infect. Dis.31, 291 (2000) Abstract 458.
   Google Scholar
• Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis.38(Suppl. 4), S341–S345 (2004).
   PubMed Web of Science ®Google Scholar
• Johnson MP, Ramphal R. β-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J. Infect. Dis.162, 981–983 (1990).
   PubMed Web of Science ®Google Scholar
• Hugues WT, Armstrong D, Bodey GP et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis.34, 730–751 (2002).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, von Lilienfeld-Toal M, Schulte S et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. Clin. Microbiol. Infect.11(Suppl. 5), 17–23 (2005).
   PubMed Web of Science ®Google Scholar
• Glasmacher AM, von Lilienfeld-Toal M, Prentice A, Khan M, Marklein G, Hahn C. Antibiotic monotherapy for unexplained fever in neutropenic patients: a meta-analysis. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, USA 2005.
   Google Scholar
• Raad II, Whimbey EE, Rolston KVL et al. A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients. Cancer77, 386–395 (1996).
   Google Scholar
• Lark RL, McNeil SA, van der Hyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin. Infect. Dis.33, 338–343 (2001).
   Google Scholar
• Zahar JR, Farhat H, Chachaty E, Meshaka P, Antoun S, Nitenberg G. Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study Clin. Microbiol. Infect.11, 724–729 (2005).
   PubMed Web of Science ®Google Scholar
• Fanourgiakis P, Vekemans M, Georgala A et al. Febrile neutropenia and Fusobacterium bacteremia: clinical experience with 13 cases. Support Care Cancer11, 332–335 (2003).
   PubMed Web of Science ®Google Scholar
• Rolston KV, Berkey P, Bodey GP et al. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch. Intern. Med.152, 283–291 (1992).
   PubMed Web of Science ®Google Scholar
• Furno P, Bucaneve G, Del Favero A. Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis. Lancet Infect. Dis.2, 231–242 (2002).
   PubMed Web of Science ®Google Scholar
• Paul M, Soares-Weiser K, Leibovici L. β lactam monotherapy versus β lactam–aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. Br. Med. J.24, 326–1111 (2003).
   Google Scholar
• Aoun M,Georgala A, Barette M et al. Focus on sepsis syndrome (SS) in febrile neutropenia (FN). Proceedings of the 6th International Symposium on Febrile Neutropenia, Brussels, Belgium 2003.
   Google Scholar
• De Jongh CA, Joshi JH, Newman KA et al. Antibiotic synergism and response in Gram-negative bacteremia in granulocytopenic cancer patients. Am. J. Med.80, 96–100 (1986).
   PubMed Web of Science ®Google Scholar
• Sepkowitz KA, Brown AE, Armstrong D. Empirical therapy for febrile, neutropenic patients: persistence of susceptibility of Gram-negative bacilli to aminoglycoside antibiotics. Clin. Infect. Dis.19, 810–811 (1994).
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Moellering RC Jr. Antibiotic synergism and antimicrobial combinations in clinical infections. Rev. Infect. Dis.4, 282–293 (1982).
   PubMedGoogle Scholar
• Gribble MJ, Chow AW, Naiman SC et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin–aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob. Agents Chemother.24, 388–393 (1983).
   PubMed Web of Science ®Google Scholar
• Brown SD, Rybak MJ. Antimicrobial susceptibility among respiratory tract pathogens from the northern states of the USA: data from year 1 of the PROTEKT US surveillance program (2000–2001). Infect. Dis. Clin. Pract.13, 179–186 (2005).
   Google Scholar
• Edmond MB, Wallace SE, McClish DK et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin. Infect. Dis.29, 239–244 (1999).
   PubMed Web of Science ®Google Scholar
• Elting LS, Rubenstein EB, Rolston KV, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin. Infect. Dis.25, 247–259 (1997).
   PubMed Web of Science ®Google Scholar
• Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrob. Agents Chemother.40, 891–894 (1996).
   Google Scholar
• Marron A, Carratala J, Alcaide F et al. High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients. J. Antimicrob. Chemother.47, 87–91 (2001).
   PubMed Web of Science ®Google Scholar
• Borok MPS, Fraser S, Vidal L, Cohen M, Leibovici L. Review: additional anti-Gram-positive antibiotics do not reduce all-cause mortality in cancer and febrile neutropenia. ACP Journal Club144, 3 (2006).
   PubMedGoogle Scholar
• Practice Guidelines Committee of the Infectious Diseases Society of America. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbid. Mortal. Week. Rep.44(R12), 1–13 (1995).
   PubMedGoogle Scholar
• Klastersky J, Paesmans M, Georgala A et al. Management with oral antibiotics in an oupatient setting of febrile neutropenic cancer patients, selected primarily but not only on the basis of a score predictive for complications. J. Clin. Oncol.24, 4129–4134 (2006).
   PubMed Web of Science ®Google Scholar
• Kern WV, Cometta A, De Bock J et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N. Engl. J. Med.341, 312–318 (1999).
   PubMed Web of Science ®Google Scholar
• Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N. Engl. J. Med.341, 305–311 (1999).
   PubMed Web of Science ®Google Scholar
• Rubinstein EB, Rolston K, Benjamin RS et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer71, 3640–3646 (1993).
   PubMed Web of Science ®Google Scholar
• Innes HE, Smith DB, Reilly SMO et al. Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer; a prospective randomised controlled single centre study. Br. J. Cancer89, 43–49 (2003).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Bamias A, Efstathiou E et al. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer103, 2629–2635 (2005).
   PubMed Web of Science ®Google Scholar
• Rolston KV, Manzullo EF, Elting LS. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia. Cancer106, 489–494 (2006).
   Google Scholar